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Abstract
Background: Eukaryotic initiation factor 4E (eIF4E) is elevated in many cancers and is a prognostic
indicator in breast cancer. Many pro-tumorigenic proteins are selectively translated via eIF4E,
including c-Myc, cyclin D1, ornithine decarboxylase (ODC), vascular endothelial growth factor
(VEGF) and Tousled-like kinase 1B (TLK1B). However, western blot analysis of these factors in
human breast cancer has been limited by the availability of fresh frozen tissue and the labor-
intensive nature of the multiple assays required. Our goal was to validate whether formalin-fixed,
paraffin-embedded tissues arranged in a tissue microarray (TMA) format would be more efficient
than the use of fresh-frozen tissue and western blot to test multiple downstream gene products.
Results: Breast tumor TMAs were stained immunohistochemically and quantitated using the
ARIOL imaging system. In the TMAs, eIF4E levels correlated strongly with c-Myc, cyclin D1, TLK1B,
VEGF, and ODC. Western blot comparisons of eIF4E vs. TLK1B were consistent with the
immunohistochemical results. Consistent with our previous western blot results, eIF4E did not
correlate with node status, ER, PR, or HER-2/neu.
Conclusion: We conclude that the TMA technique yields similar results as the western blot
technique and can be more efficient and thorough in the evaluation of several products
downstream of eIF4E.
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Background
Breast cancer remains a major cause of death among
women. The American Cancer Society's facts and figures
shows that 182,460 new cases of breast cancer will be
diagnosed in women in 2008 [1]. The number of deaths
due to breast cancer in 2008 is projected to be 40,480. In
addition, 1990 men are expected to get breast cancer and
450 to die of it in 2008. There are several risk factors for
breast cancer occurrence such as genetic susceptibility,
radiation, obesity, and alcohol use. Pathways activated in
breast cancer include Eukaryotic Translation Initiation
Factor 4E (eIF4E) pathway [2], Phosphatidylinositol-3-
kinase(PI3K)-AKT pathway [3], Mitogen-Activated Pro-
tein Kinase (MAPK) pathway [4] and the Nuclear factor-
kappaB (NFkB) pathway [5]. Our research has focused on
the role of the eIF4E in human breast cancer.
Role of eIF4E in human breast cancer
The eukaryotic translation initiation factor, eIF4E, is a 25-
kD cytosolic cap-binding protein that recognizes and
binds to the 7-methylguanosine cap in the 5'-untranslated
regions (5'-UTR) of mRNAs during the initiation of pro-
tein translation (reviewed in [6,7]). eIF4E may be consid-
ered the rate-limiting component in translation initiation
because it is found in much lower amounts than other
translation factors and is activated via mitogenic stimuli
(serum, phorbol esters, tumor necrosis factor a, and
lipopolysaccharide [6]). Several complex 5'-UTR mRNAs
involved in cell division, cell growth, and angiogenesis,
are known to be selectively translated via eIF4E, including
ornithine decarboxylase (ODC) [8], vascular endothelial
growth factor (VEGF) [9], c-Myc [10], cyclin D1 [11], and
Tousled-like kinase 1B (TLK1B) which mediates radioresist-
ance [12]. Furthermore, fibroblast cells transfected with
eIF4E develop a malignant phenotype, whereas treat-
ments aimed at inhibiting the level or activity of eIF4E
result in inhibition of tumorigenic properties [13]. eIF4E
is overexpressed in malignant breast cancer tumor lines
MDA-MB-435, MDA-MB-231, and MCF-7, but not in
non-tumor cells (MCF-10A) or epithelial cells from the
milk of a nursing mother [14]. eIF4E protein expression is
also elevated in a variety of human cancers including
breast cancer but not in stroma or in benign tissue [13].
Furthermore, eIF4E expression is elevated during hypoxia
[15], and at the invasive front in head and neck cancer and
in invasive disease [16].
Based on these observations, clinical studies have been
conducted to determine the relationship between eIF4E
overexpression (quantitated by western blot analysis) and
clinical outcome. The results indicated that patients with
high eIF4E had a statistically significant higher rate of can-
cer recurrence (n = 38, p = 0.03 log-rank test) and cancer-
related death (n = 38, p = 0.04 log-rank test) compared to
those with low eIF4E overexpression in a 40-month fol-
low-up [17]. These results were further supported in a pro-
spective trial, in which patients with high eIF4E
overexpression had a shorter disease-free survival (p =
0.004, log-rank test) and higher cancer-related deaths (p =
0.002) compared to those with low eIF4E overexpression.
Furthermore, eIF4E protein expression correlated with
increased VEGF levels and microvessel density [18]. Sig-
nificantly, eIF4E expression was independent of ER, PR,
HER-2/neu, or node status as determined by Cox propor-
tional hazard model [18,19].
Fresh-frozen vs formalin-fixed paraffin embedded tissue
As mentioned above, high eIF4E overexpression has been
associated with a worse clinical outcome [17]. However,
one of the limiting factors in that study was that it
required western blot analysis of fresh-frozen tissue.
Fresh-frozen tissue is typically scarce, especially in smaller
tumors. Furthermore, in order to conduct a multi-institu-
tional study to analyze enough samples for meaningful
results, archived specimens will be essential. In addition,
the use of paraffin-embedded archived samples would be
useful for long-term follow-up. This will enable research-
ers and clinicians to establish eIF4E as a standard prognos-
tic or diagnostic factor. Additionally, if eIF4E is
determined to be a diagnostic factor, it may be used to
personalize therapeutic care of the patient.
Tissue Microarrays
Yang and colleagues recently reported that eIF4E levels
were moderately correlated with VEGF and cyclin D1 in a
breast cancer TMA [20]. This TMA was obtained from
TARP http://www.cancer.gov/tarp/. However, although
complete histologic data was available for breast, only
limited and incomplete clinical information was availa-
ble. The goal of our present study was to validate our own
in-house TMA's by comparing eIF4E expression with
known downstream effector molecules, cyclin D1, c-Myc,
VEGF, TLK1B, and ODC. We possess complete clinical
information on each specimen, which will allow future
TMAs to be constructed for further analysis.
Materials and methods
Tissue procurement for western blot analysis
Breast cancer specimens of at least 100 mg were obtained
from the tumor core at the time of surgery from each
patient per IRB approved protocol. The specimens were
verified by the study pathologist to be invasive mammary
carcinomas. The specimens were then immediately frozen
in liquid nitrogen and stored at minus 70°C for subse-
quent assay preparations.
Construction of TMAs
The archived H&E slides used for diagnosis were reviewed
by the pathologist on the team for confirmation of diag-
nosis and selection of appropriate paraffin-embedded tis-Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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sue blocks for the construction of TMAs. Slides with
appropriate tissue of interest were selected and mapped to
define representative areas for construction of the TMA
blocks using a 1.5 mm punch size. In all, 3 TMA blocks
were constructed.
TMA block 1 consisted of the following specimens: 5 node
positive breast ductal carcinoma, 3 node negative breast
ductal carcinoma, 1 ductal carcinoma in-situ, and 1
benign breast tissue. The carcinomas (in-situ carcinoma
and the invasive ductal carcinoma cases) were punched in
triplicates and the patient-matched controls of corre-
sponding benign breast tissues were punched in dupli-
cates. For slide orientation and as additional tissue
control, normal pancreas tissue (punched in duplicate)
was also included in each TMA.
TMA block 2 consisted of the following specimens: 6 node
positive breast ductal carcinoma, 6 node negative breast
ductal carcinoma, 2 ductal carcinoma in-situ with
matched, 2 benign breast tissues as benign controls from
the 2 the patients with ductal carcinoma in-situ, and 1
benign breast tissue from a breast reduction surgery. The
invasive carcinomas were punched in triplicates. The in-
situ carcinoma cases and the matched benign controls
were punched in duplicates.
TMA block 3 consisted of the following specimens: 38
invasive ductal carcinoma patients (40 cases punched but
2 had no tumor on the TMA), 3 patients with ductal carci-
noma in-situ, and 3 normal breast tissues from breast
reduction surgeries.
Immunohistochemistry
For the immunohistochemical analysis, 5 μm thick sec-
tions were cut, warmed to 60°C, de-paraffinized in
xylene, and then rehydrated with graded ethanol. This
step was followed by antigen exposure for 20 minutes in
heated antigen retrieval solution and then the endog-
enous peroxide activity was inactivated by treating with
0.3% H2O2 in methanol. The sections were blocked for 20
min in protein block (normal goat serum in PBS, Bio-
Genex), and incubated with primary antibodies against
ODC (Sigma #O1136, diluted 1:500); eIF4E (mono-
clonal, BD Transduction Laboratories, 1:600 dilution), c-
Myc (Abcam, ab31426, 1:500 dilution), TLK1B (from De
Benedetti [21], 1:700 dilution), VEGF (Ab-3, JH121, Neo-
Marker-Labvision, 1:60 dilution), and cyclin D1 (Cell Sig-
naling #2926, 1:100 dilution) for 1 h using an automated
stainer (BioGenex I6000 Automated Staining System, San
Ramon, CA). Samples were rinsed 5 times in washing
buffer, and incubated in secondary antibody (MultiLink-
BioGenex Super Sensitive Link-Label IHC Detection Sys-
tem) for 30 min. Samples were rinsed 3 times in wash
buffer, and then incubated in horseradish peroxidase
label (BioGenex) for 15 min. Samples were rinsed 3 times
in wash buffer and then incubated in diaminobenzidine
(Dako Cytomation Liquid DAB Substrate Chromogen
System) for 5 min. Samples were rinsed 3 times in wash
buffer and counterstained in hematoxylin (Dako Cytoma-
tion Automation Hematoxylin) for 2 min.
Western Blot
Specimens were analyzed for eIF4E and TLK1B as previ-
ously described [22,23]. Briefly protein lysates from each
specimen (5–10 μg protein) were separated using 12%
denaturing gel Tris-HCL polyacrylamide gel electrophore-
sis [24]. The proteins were then electroblotted on a nylon
membrane (Immun-Blot PVDF, Bio-Rad Laboratory, Her-
cules, CA) [25]. The membranes were blocked in 3% non-
fat milk overnight. Primary incubation of the membranes
was carried out using a 1:1000 dilution of monoclonal
mouse anti-eIF4E antibody (610270; BD Biosciences, San
Jose, CA) or rabbit anti-TLK1B antibody (1:1000 dilution,
De Benedetti laboratory). Secondary incubation of the
membrane was then carried out using a 1:5000 dilution of
goat antimouse or anti-rabbit IgG tagged with horseradish
peroxidase. The blot was developed using Opti-4CN sub-
strate kit (Bio-Rad Laboratories, Hercules, CA). The blots
were scanned using the Biophotonics system (Biophoton-
ics Corp., Ann Arbor, MI). The band intensity was evalu-
ated using the Intelligent Quantifier software (Bio Image,
Ann Arbor, MI). The overexpression of eIF4E and TLK1B
was quantified as x-fold over the samples of benign tissue
from noncancer specimens run concurrently on the gel.
Analysis of TMAs
The first TMA (TMA1) was constructed to optimize anti-
body dilutions. The second TMA (TMA2) was designed
with triplicate specimens to analyze intra-individual vari-
ability. In this regard, three separate plugs from each
patient were taken from each original block and re-imbed-
ded into TMA2. Replicate breast tumor specimens were
analyzed for plug-to-plug reproducibility by staining the
TMAs immunohistochemically and quantitating them
using the ARIOL imaging system (described below). The
third TMA (TMA3) was designed to compare eIF4E to its
downstream effector proteins using a larger set of breast
cancer specimens.
ARIOL Imaging
The ARIOL imaging system (Genetix, San Jose, CA) was
used to quantify antibody staining of the TMAs. The spec-
imens were scanned at a low resolution (1.25×) and high
resolution (20×) using Olympus BX 61 microscope with
an automated platform (Prior). The slides were loaded in
the automated slide loader (Applied Imaging SL 50). The
images with high resolution were used for training and
quantification purpose. The system was trained to select
the stained and unstained cells/nuclei by the color ofJournal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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staining and shape of nuclei such that brown staining was
considered positive and blue staining was considered neg-
ative. The number of cells/nuclei stained was calculated
and represented as percentage of total cells/nuclei stained
positively. By measuring both immunostaining intensity
and percentage, data obtained are reproducible, objective
measurements of immunoreactivity. Because standardiz-
ing IHC, from the fixation of tissues to the analysis of IHC
results is critical, all immunohistochemistry data were
normalized to cytokeratin. To control for the variability in
tumor cellularity from one patient to another, and to also
control for variations in the number of tumor cells at dif-
ferent TMA spots (intra-tumoral variations), the number
of epithelial (tumor) cells present at each TMA spot as
highlighted by expression of cytokeratin 7, was used for
normalization of each protein expression studied [26].
For each protein, a score was generated based on the area
with and the intensity of the brown staining reaction. The
scores were then exported to an Excel spreadsheet for anal-
ysis. A normalized value was calculated for each protein
by dividing the recorded score for the protein by the
recorded score for cytokeratin 7 at the corresponding spot.
ER, PR, HER-2/neu analysis
Immunohistochemical staining for estrogen receptor
(ER), progesterone receptor (PR), and HER-2/neu was
performed using automated processing and staining tech-
nology (BenchMark XT IHC/ISH, Ventana). Processes
included deparaffinization, pretreatment, antibody incu-
bation, counterstaining, and coverslipping. Levels of
membranous/cytoplasmic immunostaining for Her-2/
neu, were scored using an automated cellular image anal-
ysis system (ACIS) (Clarient, San Juan Capistrano). Values
less than 1.9 are interpreted as negative and values ≥ 2.0
are interpreted as positive for HER-2/neu over-expression.
Nuclear ER and PR expression was assessed using the
ACIS; both the quantitative intensity of expression and
percentage of cells showing positive expression were
noted.
Statistical analysis
Intra-individual coefficient of variations (CV) was calcu-
lated as ratio of standard deviation over mean × 100. The
mean CV% and SD of CV for each marker was also added.
The correlation among the expression levels of eIF4E, c-
Myc, cyclin D1, ODC, TLK1B, VEGF, ER, PR, and HER-2/
neu were calculated by the Spearman rank correlation
method. These correlation coefficients were test against 0.
All two-sided p-values < 0.05 were considered as statisti-
cally significant. The strength of correlation among the
markers were classified as strong, moderate and weak for
the correlation coefficient > 0.8, 0.4–0.8, and < 0.4 respec-
tively. The statistical software used for the current study
was SAS 9.1.3. SAS Institute Inc., Cary, NC.
Results
Construction and analysis of TMAs
The first TMA was constructed in order to optimize the
immunohistochemical staining techniques and to train
the ARIOL imaging system. The criteria for successful
staining included appropriate staining to the subcellular
compartment, lack of staining in the absence of primary
antibody, increase in staining when higher concentrations
of primary antibodies were used, low staining in non-epi-
thelial derived tissue (such as stroma or fat), and low
staining in the negative controls (benign tissue). An exam-
ple of the construction of TMA3 is shown in Figure 1. The
ARIOL system first images the entire slide to show each
plug. Higher resolution images can be made by zooming
in on each plug. As shown in Figure 2, the ARIOL system
can be trained to distinguish between cytoplasmic and
nuclear staining. For example, ODC typically stains in the
cytoplasm, leaving the counter-stained nuclei predomi-
nantly blue (Figure 2). The computational software can
then scan and analyze each plug for positive staining.
Intra-individual coefficients of variances
Once these conditions were established, the second TMA
was constructed using replicate plugs in order to verify the
plug-to-plug consistency for each protein. The intra-indi-
vidual coefficients of variances (CV%) for eIF4E, c-Myc,
cyclin D1, ODC, TLK1B and VEGF were used as a measure
of plug-to-plug reproducibility (Table 1). The overall
CV% (means ± SE) was 35.8 ± 5.3%. The range of CV%
was 25.2 ± 6.1% (VEGF) up to 55.9 ± 14.2% (cyclin D1).
Since the TMAs can have up to 48 specimens, future TMAs
could be made by using up to 48 individual, 24 duplicate,
or 16 triplicate specimens (minus appropriate controls).
Based on these CV% results, TMA3 was created using indi-
vidual specimens, because we felt that the overall CV%
was reasonable and that more power could be gained by
analyzing a larger number of individual specimens.
TMA-IHC analysis: Correlation of eIF4E with downstream 
effector proteins
In TMA3, eIF4E expression levels correlated strongly with
the downstream effector proteins, c-Myc, cyclin D1, ODC,
TLK1B, and VEGF (Figures 3, 4). In Figure 3, we show a set
of human breast carcinoma specimens from TMA3 that
were either low or high for eIF4E (as measured by IHC).
Their positions on TMA3 are marked in Figure 1. Then, the
IHCs for the same specimens are also shown for the
downstream effector proteins. Generally, specimens that
possessed high eIF4E protein expression also exhibited
high expression of c-Myc, cyclin D1, TLK1B, VEGF, and
ODC. Likewise, specimens that expressed low amounts of
eIF4E protein also expressed low amounts of c-Myc, cyclin
D1, TLK1B, VEGF, and ODC. The rho values for eIF4E
compared to c-Myc, cyclin D1, TLK1B, VEGF, and ODC
were 0.880, 0.863, 0.729, 0.699, and 0.799 respectively,Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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Low magnification (100 ×) of human breast cancer specimens in TMA3 stained immunohistochemically for ODC Figure 1
Low magnification (100 ×) of human breast cancer specimens in TMA3 stained immunohistochemically for 
ODC. Boxes indicate specimen type. The specimens marked "low 4E" and "high 4E" are also shown in Figure 3. The top right 
corner of the TMA was left blank, and a pancreas specimen was placed in the lower right hand corner of the TMA in order to 
verify proper orientation. IDC, intraductal carcinoma; DCIS, ductal carcinoma in situ.Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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and all these comparisons were statistically significant at
p ≤ 0.0001 (Figure 4A–E).
Western blot analysis: Correlation of eIF4E with TLK1B
We have previously shown by western blot analysis that
the expression of eIF4E correlated with that of TLK1B [23].
As further validation of our TMA results, we also com-
pared eIF4E with TLK1B using the corresponding fresh-
frozen specimens from the same tumors as those used for
TMA3 (Figure 4F). Due to limited amounts of fresh-frozen
specimens, the other proteins were not analyzed. Protein
expressions of eIF4E to TLK1B were positively correlated
(rho value 0.485, p value 0.0054).
Non-correlation to independent markers
We have previously demonstrated that western blot anal-
ysis of eIF4E did not correlate with node status, ER, PR, or
HER-2/neu [18,19]. In the current study, expression of
eIF4E (by both TMA-IHC and western blot) was also com-
pared to ER, PR, and HER-2/neu expression. There was no
correlation of eIF4E on TMA3 with any of these independ-
ent markers by either TMA-IHC or western blot analysis of
eIF4E (Table 2).
Discussion
In the current study, we have analyzed the expression of
eIF4E along with 5 of its downstream effector proteins in
human breast carcinoma specimens using immunohisto-
chemical analysis of TMAs. The downstream effector pro-
teins c-Myc, cyclin D1, ODC, TLK-1B, and VEGF were
positively correlated with eIF4E when analyzed by IHC. As
shown previously [27], western blot analysis of eIF4E cor-
related with TLK1B protein expression. At the same time,
eIF4E expression (determined by both western blot and
TMA-IHC) did not correlate with ER, PR or HER-2/neu.
Consistent with these results, the lack of correlation of
eIF4E (detected by western blot) with ER, PR, and HER-2/
neu was previously reported [18,19]. Our results confirm
and extend the results previously described by Yang and
colleagues [20]. In their study, which utilized a multi-
tumor TMA from TARP http://www.cancer.gov/tarp/, they
found eIF4E, VEGF, and cyclin D1 were elevated in breast
tumors compared to combined normal tissues [20]. The
authors also found that eIF4E levels were moderately cor-
related with VEGF and cyclin D1 expression in breast
(Spearman's rank correlation) [20]. Among the major dif-
ferences between the two studies: this study focused solely
on breast cancer, and included validation of western blot
and IHC analysis of the same samples. We also verified
coefficients of variance to demonstrate plug-to-plug
reproducibility. Furthermore, we examined a broader
range of downstream proteins, and included more nega-
tive controls. Also, we used the ARIOL imaging system
High magnification (400 ×) of human breast cancer specimen  from TMA3 stained immunohistochemically for ODC Figure 2
High magnification (400 ×) of human breast cancer 
specimen from TMA3 stained immunohistochemi-
cally for ODC. Note the predominantly cytosolic staining 
of ODC, whereas the nuclei were counterstained blue.
Table 1: Intra-individual Coefficients of Variance for TMA2 (CV%)a
Mean IOD SD IOD Mean CV% SD CV% SE CV% n
1. eIF4E 62.7 26.2 26.4 24.5 7.8 10
2. c-Myc 68.1 23.3 28.1 16.1 4.9 11
3. Cyclin D1 51.2 32.5 55.9 45.1 14.2 10
4. ODC 55.2 23.4 30.7 27.2 8.6 10
5. TLK1B 38.9 26.3 46.9 38.5 11.6 11
6. VEGF 24.8 15.3 25.2 18.4 6.1 9
Overall 35.5 12.8 5.2 6
aIntra-individual coefficient of variations (CV) was calculated as ratio. of standard deviation over mean × 100. The mean CV% and SD of CV for each 
marker was also added. The N's were added up in Table 1 as the number of replicate cases. Only those specimens in which 2–3 plugs could be 
analyzed are listed. So, in TMA2, there were up to 12 different cases, but only those that resulted in duplicate or triplicate plugs were analyzed for 
CV%. The overall mean and SD for integrated optical density (IOD) for each protein is also listed.Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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Representative example of human breast cancer specimens from TMA3 that expressed either low (left panel) or high (right  panel) eIF4E Figure 3
Representative example of human breast cancer specimens from TMA3 that expressed either low (left panel) 
or high (right panel) eIF4E. Matching specimens from the same patient are shown for c-Myc, cyclin D1, ODC, TLK1B, and 
VEGF (200 × magnification).Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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Correlation of immunohistochemical expression of eIF4E vs c-Myc [A], cyclin D1 [B], ODC [C], TLK1B [D], VEGF [E] from  TMA3 Figure 4
Correlation of immunohistochemical expression of eIF4E vs c-Myc [A], cyclin D1 [B], ODC [C], TLK1B [D], 
VEGF [E] from TMA3. Figures represent the integrated optical density (IOD) of immunohistochemical staining intensity 
normalized to cytokeratin. Protein expression of eIF4E and TLK1B were also compared by western blot analysis [F], in which 
values represent expression of eIF4E and TLK1B as fold- over benign. All comparisons were done using Spearman's rank cor-
relation. Rho- and p- values for each comparison are displayed in each panel.Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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whereas they used ACIS. The strength of these two studies
supports the idea that IHC can be used in a TMA format
for evaluating critical oncogenic proteins.
In comparing western blot to IHC, there are advantages
and disadvantages to both procedures. One advantage to
western blot, traditionally, is that it has provided a greater
dynamic range for quantitation than IHC. This is espe-
cially true, historically, as IHC has been semi-quantitative
and subject to scoring methods. However, with the wider
availability of IHC quantitation systems such as ARIOL,
IHC has become more quantitative. This also provides
potential standardization between different research insti-
tutions. The use of TMAs rather than individual IHCs for
each specimen also provides institutions the ability to
analyze a larger set of specimens at a time using similar
staining and quantitation procedures. Another advantage
to western blot, however, is that the molecular weights of
the proteins can be estimated based on the molecular
weight standards that are also resolved on the gel. This is
particularly important if the antibodies exhibit non-spe-
cific staining. The protein of interest can be isolated from
the non-specific staining and quantitated. The best way to
overcome the problem of non-specific staining in IHC is
to use the most specific antibodies available and to opti-
mize the dilutions of antibodies and other staining condi-
tions. Comparisons of positive and negative controls also
help confirm specificity. One disadvantage to western blot
is that unless specimens were prepared by isolation of spe-
cific cells through differential centrifugation or density
gradients, they typically contain a heterogeneous mixture
of cells (e.g., stromal component, adipocytes, epithelial
cells, necrotic tissue, vascular tissue, etc.) and may not dis-
tinguish between the different compartments of the cell.
With the ARIOL imaging system, different regions of tis-
sue can be selected and quantitated, so as to avoid sec-
tions that contain non-regions of interest. Furthermore,
ARIOL also possesses the training capability to select
nuclear vs. cytoplasmic staining. Also, large amounts of
precious tissue are required for western blots, which may
not be readily available. TMAs or IHC require less sample,
and archived specimens can be used for a longer follow-
up period. An average of 30–40 serial sections can be cut
from one of our TMAs, such that multiple comparisons
can be drawn among different proteins of interest. For
these reasons, we believe that TMAs will provide a reason-
able method for analyzing large numbers of specimens.
It has been shown that eIF4E is an independent prognos-
tic factor in breast cancer [18]. We had selected tumor
samples that showed a wide range of eIF4E protein expres-
sion by western blot which was significantly higher than
the normal tissues. The TMA staining showed that 4E was
elevated in breast tissues compared to the normal tissues.
Over-expression of eIF4E leads to the translation of struc-
tured 5' UTR mRNAs which include c-Myc, cyclin D1,
ODC, TLK1B and VEGF. These proteins have been studied
individually in breast cancer patients. The results of the
current study have shown that when eIF4E was elevated
there was a corresponding rise in the protein expression of
c-Myc, cyclin D1, ODC, TLK1B and VEGF. Thus eIF4E
modulates the expression of the downstream effector pro-
teins that regulate processes up regulated in cancer cells
like the cell cycle, survival and cell growth. On the other
hand, previous results using western blot analysis of eIF4E
demonstrated that it did not correlate with node status,
ER, PR, or HER-2/neu expression [18,19]. As a negative
control for our current study, we also showed that IHC
analysis of eIF4E on TMA3 also did not correlate with ER,
PR, or HER-2/neu. Western blot analysis of eIF4E from the
corresponding samples showed similar results.
Conclusion
To our knowledge, this is the first time that a correlation
has been made in a single study between eIF4E, c-Myc,
cyclin D1, ODC, TLK1B and VEGF. Since the samples were
Table 2: Lack of correlation of ER, PR, or HER-2/neu with eIF4E
95% Confidence Interval
Rho Value Lower Upper n P
TMA expression of eIF4Ea
eIF4E and ER -0.137 -0.469 0.228 31 0.452
eIF4E and PR -0.069 -0.413 0.293 31 0.707
eIF4E and HER-2/neu -0.013 -0.406 0.384 25 0.949
Western blot expression of eIF4Eb
eIF4E and ER -0.192 -0.479 0.132 39 0.237
eIF4E and PR -0.295 -0.558 0.023 39 0.069
eIF4E and HER-2/neu -0.143 -0.469 0.216 32 0.425
a For the first three rows, comparisons were made of immunohistochemical staining of each protein normalized to cytokeratin to ER, PR, and HER-
2/neu. bLast three rows, comparison of protein expression of eIF4E assayed by western blot (fold- over benign) to ER, PR, and HER-2/neu. All 
comparisons were done using Spearman's Rank Correlation.Journal of Experimental & Clinical Cancer Research 2009, 28:5 http://www.jeccr.com/content/28/1/5
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obtained from a geographical area in which patients typi-
cally present with advanced stage breast cancer [28], this
study has shown the major oncoproteins that are upregu-
lated in this population. The hospital also possesses the
clinical information as well as the outcome of these
patients. This study becomes more relevant when we can
correlate the results from the TMA study to the clinical
outcome as we follow up with these patients. In conclu-
sion, eIF4E preferentially upregulates gene products that
are involved in worse clinical outcome in breast cancer,
head and neck cancer, and others. To study each down-
stream effector protein by western blot using fresh-frozen
tissue is cumbersome and simply not feasible for many
reasons, including long-term follow-up. There is an urgent
need for clinicians to be able to examine a set of biomar-
kers such as eIF4E and downstream effector molecules in
order to set a current standard for prognosis.
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